ArticleMedical oncology (Northwood, London, England)2026
Farnesol suppresses hypoxia associated EMT signaling and impairs 3D spheroid integrity in A549 lung adenocarcinoma cells.
Article in Medical oncology (Northwood, London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Lung cancer remains the leading cause of high cancer incidence and mortality worldwide. Among lung cancers, non-small cell lung cancer (NSCLC) is the predominant subtype accounting for majority of cancer deaths. The invasive and metastatic behavior of NSCLC largely contributes to its aggressive nature and therapeutic resistance. Farnesol (FAR), a naturally occurring sesquiterpene, has shown anticancer activity in several malignancies however, its mechanistic role in NSCLC invasion and metastasis remains not fully understood. In the present study, we investigated the effect of farnesol on A549 lung adenocarcinoma cells through in vitro approaches involving protein-protein/gene interactions, molecular analysis and 3D screening. Scratch assay and transwell invasion assays were performed to evaluate the effect of farnesol on A549 cell migration and invasion. Immunofluorescence staining analysis were employed to assess the anti-angiogenic potential of farnesol followed by western blotting and real-time PCR to validate the efficacy of farnesol in regulating invasion and metastasis associated markers. Farnesol significantly reduced the viability of A549 cells in a dose-dependent manner, with an IC₅₀ of 21.5 µg/mL inducing cell shrinkage and loss of cell density. Scratch and matrix-assisted transwell invasion assays demonstrated marked inhibition of migration and invasion with increased nonmigratory spaces in farnesol-treated group compared to control. Molecular analysis confirmed upregulation of E-cadherin, downregulation of VEGF, PCAF, COX2, and suppression of mesenchymal and matrix remodeling markers. Farnesol reduced spheroid diameter, dissociation of spheroid integrity and induced of apoptosis at concentrations above 125 µg/mL. Collectively, our findings suggest that farnesol potentially inhibits A549 cell migration, invasion and metastasis, highlighting farnesol as an effective therapeutic candidate for the treatment of lung adenocarcinoma.
Indexed as
Identifiers
42709345What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.